Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 2—February 2014

Lethal Factor and Anti-Protective Antigen IgG Levels Associated with Inhalation Anthrax, Minnesota, USA

Mark D. SprenkleComments to Author , Jayne Griffith, William Marinelli, Anne E. Boyer, Conrad P. Quinn, Nicki T. Pesik, Alex Hoffmaster, Joseph Keenan, Billie A. Juni, and David D. Blaney
Author affiliations: Hennepin County Medical Center, Minneapolis, Minnesota, USA (M.D. Sprenkle, W. Marinelli); Minnesota Department of Health, St. Paul, Minnesota, USA (J. Griffith, B.A. Juni); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.E. Boyer, C.P. Quinn, N.T. Pesik, A. Hoffmaster, D.D. Blaney); University of Minnesota, Minneapolis (J. Keenan)

Main Article

Table 2

Antimicrobial drugs administered to patient with inhalational anthrax diagnosed on hospital day 3, Minnesota, USA, 2011*

Antimicrobial drug Dose Route, frequency Hospital and post-hospitalization days medication administered
Ceftriaxone 2.0 g IV, every 24 h 1–4
Azithromycin 500 mg IV, every 24 h 1–3
Ciprofloxacin 400 mg IV, every 12 h 2–26
Meropenem 1.0 g IV, every 8 h 3–4
Vancomycin 2.0 g IV, once 3
Clindamycin 900 mg IV, every 8 h 4–14
Rifampin 300 mg Enteral, every 12 h 4–8
Meropenem 1.0 g IV, every 8 h 8–22
Ciprofloxacin 500 mg Oral, every 12 h 26; PH 1-35†

*IV, intravenous; hospital day, number of days in hospital including day of admission; PH, post-hospitalization days.
†IV medication was discontinued and oral medication was started on day of discharge (hospital day 26) and continued for 35 additional days to complete 60 days of therapy.

Main Article

Page created: January 17, 2014
Page updated: January 17, 2014
Page reviewed: January 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.